dc.contributor.author | Kanlıöz, Murat | |
dc.contributor.author | Ekici, Uğur | |
dc.date.accessioned | 2020-08-05T20:05:06Z | |
dc.date.available | 2020-08-05T20:05:06Z | |
dc.date.issued | 2020 | en_US |
dc.identifier.issn | 0960-8923 | |
dc.identifier.issn | 1708-0428 | |
dc.identifier.uri | https://hdl.handle.net/11363/2338 | |
dc.description | Document Information
Language:English
Accession Number: WOS:000532631600003
PubMed ID: 32405906 | en_US |
dc.description.abstract | Purpose To analyze how considering the structure of normotonic pylorus (NP) or hypotonic pylorus (HP) contributes to treatment success in patients administered gastric botulinum toxin A for weight loss. Materials and Methods We measured body mass indexes (BMIs) of the patients who applied for gastric botulinum toxin A (BTA) for weight loss, before and 6 months after the procedure. The patients' pylori were classified as normotonic pylorus (NP) if, during endoscopy, they had a normal peristaltic motion and was closing completely, and as hypotonic pylorus if they were not closing properly or were aperistaltic. We compared the patients' mean pre-operative and 6-month post-operative BMIs. The groups were compared using the chi-square test where a p < 0.05 was considered significant. Results The study included 178 patients administered gastric BTA. In the assessment made without considering the pyloric structure, the mean BMI decreased from 34.76 +/- 7.65 to 33.09 +/- 7.80 kg/m(2), while the difference was not statistically significant (p < 0.06). Conversely, in the analysis performed considering the structure of pylorus, the mean pre-operative BMI of the 45 patients with HP structure was 35.16 +/- 7.07 kg/m(2) which decreased to 35.11 +/- 7.03 kg/m(2) 6 months after the procedure; hence, the difference was not statistically significant (p < 0.7). The mean pre-operative BMI of the 133 patients with NP structure, 34.63 +/- 7.84 kg/m(2), decreased to 32.40 +/- 8.05 kg/m(2) 6 months after the procedure and the difference was statistically significant (p < 0.05)*. Conclusion We advise to be selective in BTA administration and to administer BTA to the patients who, endoscopically, have a NP structure. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | SPRINGER, ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES | en_US |
dc.relation.isversionof | 10.1007/s11695-020-04556-7 | en_US |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.rights | Attribution-NonCommercial-NoDerivs 3.0 United States | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/3.0/us/ | * |
dc.subject | Normotonic pylorus | en_US |
dc.subject | Hypotonic pylorus | en_US |
dc.subject | Gastric Botox | en_US |
dc.subject | Obesity | en_US |
dc.subject | INTRAGASTRIC INJECTION | en_US |
dc.subject | MIDAZOLAM | en_US |
dc.title | How Taking into Account the Pyloric Tonus Contributes to Treatment Success While Administering Gastric "Botulinum Toxin A" for Weight Loss | en_US |
dc.type | article | en_US |
dc.relation.ispartof | OBESITY SURGERY | en_US |
dc.department | Sağlık Bilimleri Yüksekokulu | en_US |
dc.authorid | https://orcid.org/0000-0003-4271-184X | en_US |
dc.authorid | https://orcid.org/0000-0002-2660-3120 | en_US |
dc.identifier.volume | 30 | en_US |
dc.identifier.issue | 9 | en_US |
dc.identifier.startpage | 3365 | en_US |
dc.identifier.endpage | 3369 | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |